# A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06384807/  
OnCo record `nct06384807` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cemiplimab in advanced solid tumours, run by Biohaven Therapeutics Ltd., now recruiting.

## Summary

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06384807 by Biohaven Therapeutics Ltd., with 500 participants planned, started 2024-04-22 and due to reach its primary completion in 2028-02. Interventions recorded: BHV-1510 and Cemiplimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06384807
- Phase: 1/2
- Setting: A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors
- Sponsor: Biohaven Therapeutics Ltd.
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT06384807: https://clinicaltrials.gov/study/NCT06384807

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06384807.json